Department of Pharmacoeconomics and Social Pharmacy, Poznań University of Medical Sciences, Dąbrowskiego 79 St., 60-529 Poznań, Poland.
Department of Pharmacoeconomics and Social Pharmacy, Poznań University of Medical Sciences, Dąbrowskiego 79 St., 60-529 Poznań, Poland.
Public Health. 2017 Jul;148:49-55. doi: 10.1016/j.puhe.2017.03.003. Epub 2017 Apr 7.
Despite its low prevalence, cystic fibrosis (CF) may have a considerable impact on healthcare system expenditures in terms of direct healthcare costs and lost productivity. This study was aimed at calculation of costs associated with CF treatment in Poland, as well as at comparison of average costs of treatment of CF patients in selected countries, taking into account the purchasing power parity.
Retrospective study.
The researchers undertook a retrospective study of adult patients with CF taking into account the broadest social perspective possible. Medical and non-medical direct costs as well as indirect costs were calculated. CF costs estimated by researchers from other countries over the last 15 years were also compared.
Total annual treatment cost per one CF patient in Poland was on average EUR 19,581.08. Costs of treatment of CF patients over the last 15 years varied between the countries and ranged from EUR 23,330.82 in Bulgaria to EUR 68,696.42 in the United States.
CF is an international problem. The data in this study could be the baseline for integrated and harmonised approaches for periodical assessment of the future impact of new public policies and interventions for rare diseases at the national and international levels.
尽管囊性纤维化(CF)的患病率较低,但就直接医疗成本和生产力损失而言,其对医疗保健系统支出可能具有相当大的影响。本研究旨在计算波兰 CF 治疗相关费用,并考虑购买力平价,比较选定国家 CF 患者治疗的平均费用。
回顾性研究。
研究人员对成年 CF 患者进行了回顾性研究,尽可能从广泛的社会角度考虑。计算了医疗和非医疗直接成本以及间接成本。还比较了过去 15 年来其他国家研究人员估算的 CF 成本。
波兰每位 CF 患者的年平均治疗费用为 19581.08 欧元。过去 15 年各国 CF 患者的治疗费用存在差异,从保加利亚的 23330.82 欧元到美国的 68696.42 欧元不等。
CF 是一个国际性问题。本研究中的数据可以作为基准,用于定期评估新的公共政策和干预措施对国家和国际层面罕见病未来影响的综合和协调方法。